---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009911"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:00.378048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized

## Summary
- BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.
- Significant reductions in IL-6 (44%) and fibrinogen (30%) observed, indicating downstream inflammatory cascade suppression.
- BGE-102 well tolerated with no dose-limiting toxicities; favorable safety profile.
- Phase 1 completion and Phase 2a initiation in obese patients with CV risk factors expected in 1H 2026.
- Patent issued covering additional composition of matter and novel NLRP3 binding site.

## SEC filing metadata
- accession: 0001193125-26-009911
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526009911/0001193125-26-009911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526009911/bioa-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009911
- JSON: https://secwatch.observer/filing/0001193125-26-009911.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.